Until law, GLP-1 drugs were used to treat diabetes, obesity and even the recent evidences suggest that it could as well be used to treat chronic kidney problems. There is yet another research, published in JAMA Psychiatry on February 25, titled Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial that explores if GLP-1 receptor agonist semaglutide reduce alcohol consumption and cravings in adults with alcohol use disorder.

What Do Studies Say?

The research was conducted over a period of 9 weeks, where in the randomized clinical trial, the participants who were administered semaglutide, it led to reductions in some but not all measures of weekly consumptions. It also reduced weekly alcohol and craving related to placebo, and also led to a greater relative reduction in cigarettes per day.

The research also found that weekly injections of semaglutide, which is the active ingredient in weight loss drugs like Wegovy also helped reduce cravings in people with alcohol use disorder.

The lead author Christian Hendershot said that these findings will help in developing new approaches to treat alcoholism. "Two drugs currently approved to reduce alcohol consumption aren't widely used. The popularity of Ozempic and other GLP-1 receptor agonists increases the chances of broad adoption of these treatments for alcohol use disorder," said Hendershot in news release by the University of Southern California's Institute for Addiction Research, where he is the director.

The study is government-funded research and was funded by the National Institute on Alcohol Abuse and Alcoholism, part of the National Institutes of Health.

How Was The Study Conducted?

The study was small, and took in account for only 48 adults over two months, thus experts say that it is not yet clear how safe these drugs are for people who do not need to lose weight. Though the results do add up with the evidence form animal studies on drugs like Ozempic and Wegovy on how it helps manage cravings, not just for food, but also for tobacco and alcohol. Scientists are also studying these drugs on smokers, people with opioid addiction and cocaine users.

Co-author Dr Klara Klein of the University of North Carolina at Chapel Hill who treats people with obesity and diabetes said, "This is such promising data. And we need more of it. We frequently will hear that once people start these medications that their desire to drink is very reduced, if not completely abolished."

Why Does It Work So Well Against Alcoholism?

The GLP-1 receptor agonists work by mimicking hormones GLP-1 in the gut and brain that regulates appetite and feelings of fullness. This response is what helps one lose weight, and what helps one curb their craving for alcohol. These drugs that mimic the functioning of your brain, which is responsible to tell your body when to stop consuming, are the same hormones that tell your body about other kinds of consumptions, including alcohol. Therefore by consuming the weight loss drugs one can treat alcohol use disorder.

However, the researchers have pointed out on the limited data on the research and have suggested to continue using the three approved drugs by the National Institute on Alcohol Abuse and Alcoholism and Substance Abuse and Mental Health Services Administration, namely, Disulfiram, Naltrexone, and Acamprosate to treat alcohol use disorder until large studies confirm these findings.

Michigan health officials say that they may have identified the possible source behind one of the largest Cyclosporiasis outbreaks the state has ever recorded. Thousands of people were sickened by a parasitic infection that can cause severe, watery, or even “explosive” diarrhea.

Source Behind Cyclospora Outbreak Traced

On July 13, the Michigan Department of Health and Human Services (MDHHS) announced preliminary findings from its investigation point to lettuce or other salad greens as the possible source of Cyclospora outbreak.

However, officials stressed that the investigation is in progress, and no specific product, grower, distributor, or supplier has yet been identified for certain.

Health officials also interviewed more than 1,000 patients to identify common exposures.

Early analysis also repeatedly identified lettuce and salad greens as foods consumed before illness, prompting the state to issue precautionary guidance while the investigation continues.

"Although we do not have a definite product identified as the source of the outbreak, we want to let Michiganders know what we have learned so far so they can take steps to protect their families," said Dr. Natasha Bagdasarian, Michigan's chief medical executive, in a state statement.

Also read: As Cyclospora Cases Surge In The US, Expert Explains Why India's Monsoon Raises Risk Of The Parasitic Infection

Cyclospora Cases Continue To Surge

The outbreak has continued to expand at an extraordinary pace since late June. As of July 13, Michigan reported 2,640 cases of Cyclosporiasis, with 44 hospitalizations.

No deaths have been reported so far. The number represents a dramatic increase from the state's usual annual number, which is around 40 to 50 cases.

Preventing Cyclospora

Cyclospora is a parasite that infects people after they consume food or water contaminated with human feces containing the parasite's eggs (oocysts).

Although the illness is usually not life-threatening, it can cause prolonged diarrhea, stomach cramps, nausea, fatigue, bloating, and weight loss.

According to recent reports, fresh produce like salad greens and lettuce are being considered the most common source of infection, though contaminated water can also spread the parasite.

Also read: Explosive Diarrhea Parasite Spreads Across US: Why CDC Is Unable To Find The Source?

Health officials have advised people to avoid fresh produce. Previous Cyclospora outbreaks in the US have frequently been linked to imported fresh produce, including:

• Basil

• Cilantro

• Mesclun lettuce

• Raspberries

• Snow peas

How To Clean Fresh Produce Safely?

While washing produce cannot eliminate all risks, experts say it can reduce contamination. They advised washing fruits and vegetables thoroughly under clean running water and washing hands before and after handling fresh produce.

According to the Michigan Department of Health and Human Services, cooking produce whenever possible during an active outbreak is crucial, as heating food to at least 158°F (70°C) kills Cyclospora.

For specific produce, it suggested:

• Cilantro and basil: Separate the leaves and rinse each thoroughly under running water.

• Green onions: Trim off the roots, remove the outer layer, and rinse well.

• Snow peas: Rub the surface gently while washing under running water.

• Raspberries: Because of their delicate, uneven surface, raspberries are difficult to clean thoroughly. Cooking them in pies or jams is safer. Freezing may reduce the number of parasites but is unlikely to eliminate them completely.

• Leafy greens: If possible, choose whole heads of lettuce instead of bagged salad mixes. Discard the outer leaves and wash the remaining leaves under running water before eating.

Due to climate change, the range of disease-carrying ticks across Canada have increased. Health experts have recently warned about a lesser-known infection that is spreading across the country rapidly. It is called anaplasmosis.

For years, Lyme disease has dominated conversations around tick bites. Experts are now saying that another illness transmitted by the same black-legged tick is spreading into new regions as warmer temperatures create favorable conditions for ticks to thrive.

Tick-Borne Infection Plagues Canada

The warning comes after a recently published report in the Canadian Medical Association Journal (CMAJ) highlighted anaplasmosis as an emerging disease in Canada. Experts urged healthcare providers to diagnose it early as delayed treatment can lead to severe complications.

The report described a patient who developed heart inflammation (myocarditis), after contracting the infection, highlighting the fact that while many cases are mild, some can become life-threatening.

What Is Anaplasmosis?

Anaplasmosis is caused by the bacterium Anaplasma phagocytophilum. It is transmitted through the bite of infected black-legged ticks (Ixodes scapularis) and western black-legged ticks (Ixodes pacificus).

Unlike Lyme disease, which primarily affects the skin, joints and nervous system, anaplasmosis infects white blood cells, weakening the body's immune system.

The symptoms of anaplasmosis commonly develop within one to two weeks after a tick bite and often resemble the flu. They include:

• Fever and chills
• Severe headache
• Muscle aches
• Fatigue
• Nausea or loss of appetite

Also read: Bella Hadid Opens Up About Challenges Of Living With Lyme Disease

Why Anaplasmosis Cases Are Rising In Canada?

Warmer and longer spring and summer and shorter winters are creating the ideal breeding grounds for black-legged ticks. These ticks are expanding farther north into regions where they previously could not survive.

At the same time, warmer conditions are extending the period during which ticks remain active. Public health officials say that ticks can now be active whenever temperatures remain consistently above freezing.

The Public Health Agency of Canada has reported that the geographic range of ticks carrying diseases such as Lyme disease, anaplasmosis and babesiosis continues to expand across several provinces, including Ontario, Quebec, Manitoba, New Brunswick and parts of Atlantic Canada.

Early Detection And Diagnosis Are The Key

Although many people recover completely with prompt treatment, anaplasmosis, if left untreated, can cause serious complications affecting the lungs, kidneys, nervous system and heart.

Older adults, people with weakened immune systems and those whose treatment is delayed face the highest risk of severe illness.

Canadian health authorities recommend that treatment begin as soon as doctors suspect anaplasmosis rather than waiting for laboratory confirmation, since early intervention significantly improves outcomes.

Protecting yourself during tick season is one of the ways to ward off risk of infection. Health officials recommend several simple precautions to reduce the risk of tick bites:

• Wear long sleeves and long pants in wooded or grassy areas.
• Apply insect repellents containing DEET or icaridin.
• Perform thorough tick checks after spending time outdoors.
• Remove attached ticks immediately.

As Canada's climate continues to warm, experts say the country's tick-borne disease landscape is changing rapidly. While Lyme disease remains the most recognized threat, physicians warn that anaplasmosis is no longer a rare infection.

A new safety analysis has found that Wegovy, the recently launched blockbuster weight loss medication containing semaglutide, may cause a rare but dangerous eye condition that can lead to sudden and permanent vision loss.

The analysis, published in the British Journal of Ophthalmology, compared Wegovy, semaglutide tablets and other GLP-1 drugs like Ozempic by examining more than 30 million reports from the U.S. Food and Drug Administration's Adverse Event Reporting System (FAERS) submitted between 2017 and 2024.

Scientists found a safety signal that linked semaglutide medicines to non-arteritic anterior ischemic optic neuropathy (NAION), also known as eye stroke.

Wegovy More Likely To Cause Blindness Than Ozempic

The signal appeared to be nearly five times stronger for Wegovy than for Ozempic, despite both medicines containing the same active ingredient, semaglutide.

NAION occurs when blood flow to the optic nerve suddenly gets reduced, causing damage to the nerve responsible for transmitting visual information from the eye to the brain. The patient experiences painless vision loss in one eye.

While some patients experience partial improvement, the vision loss is frequently permanent. There is currently no proven treatment to reverse the damage.

Researchers state that the findings do not prove that Wegovy causes NAION. Instead, they observe a typical signal, meaning an unexpected pattern observed in a large safety database that requires immediate further investigation.

Such pharmacological analyses are useful for identifying rare and adverse side effects that may not emerge during clinical trials.

Why Wegovy Poses A Greater Risk Of Rare Blindness?

Also read: Novo Nordisk Launches Awiqli In India: All About The World's First Once-Weekly Insulin

The stronger link observed with Wegovy and NAION compared with Ozempic has also raised new questions. Both drugs contain semaglutide, but Wegovy is prescribed at higher doses for obesity, while Ozempic is used to treat type 2 diabetes.

Researchers say that factors such as higher dosing, differences in patient populations, or underlying health conditions could help explain the disparity, although more research is needed.

The latest findings build on growing scientific interest in the potential eye-related risks of GLP-1 receptor agonists.

Previous observational studies have also reported an increased risk of NAION among semaglutide users, prompting regulators in Europe to add the condition as a very rare side effect to semaglutide product information last year.

Health experts emphasize that patients should not stop taking Wegovy without consulting their healthcare provider. For most users, the drug's benefits in managing obesity and reducing associated health risks are likely to outweigh the extremely rare risk of developing NAION.

However, anyone taking Wegovy who experiences sudden blurred vision or loss of vision should seek immediate medical attention.

Wegovy Manufacturer Explores Semaglutide Implant

The GLP-1 medication industry is in a boom. Novo Nordisk, the maker of GLP-1 medicines like Ozempic and Wegovy, is currently exploring a new way to deliver weight-loss treatment that could reduce the need for weekly injections.

The implant, known as NPM-139, is a miniature device developed using Vivani Medical's proprietary NanoPortal technology. Rather than requiring patients to inject semaglutide every week, the tiny implant is placed beneath the skin and slowly releases the medication over an extended period.

If successful, it could mark a significant step toward making GLP-1 drug more convenient for people living with obesity.